Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Revenue is projected to grow by 6.5% per year, notably slower than the US market average of 10.5%. The company's current Price-To-Sales ratio of 2.7x is well above peers and the healthcare industry average. With a share price of $31.63 against an estimated fair value of $60.95, investors are left weighing narrowing losses and a discounted price against ongoing challenges to profitability and moderate growth in a competitive landscape. See our full analysis for Castle Biosciences. The next section will stack up these latest results against the dominant market narratives, highlighting areas where consensus might be confirmed or surprised by the numbers. See what the community is saying about Castle Biosciences NasdaqGM:CSTL Revenue & Expenses Breakdown as at Nov 2025 Margins Face Pressure from Rising Expenses Sales, marketing, and general expenses are climbing as Castle Biosciences expands commercially and adjusts wages for inflation. This is cutting into profitability as ma
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive YearGlobeNewswire
- New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- 11/26/25 - Form 4
- CSTL's page on the SEC website